Publications by authors named "P M Newsome"
Article Synopsis
- The study investigates the effects of face masks on emotion recognition, especially during the COVID-19 pandemic, using a task that assessed responses to both masked and unmasked faces showing emotions like fear, sadness, and anger.
- Participants included 119 college students, 30 children, and 31 fathers, with some undergoing neuroimaging while performing the task; results showed less accurate emotion recognition for masked faces, particularly sad ones.
- Neural responses indicated greater activation in areas of the brain associated with emotion processing when viewing sad masked faces, and among fathers, this activation correlated with stress and depression; overall findings highlight the impact of mask-wearing on emotional understanding across various age groups.
Background: Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction-associated steatohepatitis (MASH).
Aims: To describe the trial design and baseline characteristics of the 'Effect of Semaglutide in Subjects with Non-cirrhotic Non-alcoholic Steatohepatitis' (ESSENCE) trial (NCT04822181).
Methods: ESSENCE is a two-part, phase 3, randomised, multicentre trial evaluating the effect of subcutaneous semaglutide 2.
Article Synopsis
- Scientists studied a health problem called MASH, which affects people's livers, and worked on two tests to help doctors tell if someone has it.
- They looked at data from over 3,000 people to make sure their first test, called acMASH, worked well, and then created a new test called acFibroMASH to find more severe cases.
- The new acFibroMASH test was better at predicting who might have future liver problems compared to another test, showing it's a useful tool for doctors to keep patients healthy.
Article Synopsis
- Gremlin-1 has been linked to liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) by inhibiting BMP signaling, making it a potential focus for therapy.* -
- In studies using rat and human models, blocking Gremlin-1 with antibodies did not reduce liver inflammation or fibrosis, despite its increased presence in specific myofibroblast cells.* -
- Findings indicate that Gremlin-1 does not significantly contribute to liver fibrosis development and is not a viable target for treatment due to its limited role in the disease process.*